Cita APA (7a ed.)
Kankam, M., Griffin, R., Price, J., Michaud, J., Liang, W., Llorens, M. B., . . . Vilardell, D. (2020). Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects. Advances in Therapy, 37(5), 2373-2390.
Cita Chicago Style (17a ed.)
Kankam, Martin, Rhonda Griffin, Jeffrey Price, Josée Michaud, Wei Liang, Mariona Bassas Llorens, Ana Sanz, Bradley Vince, y David Vilardell. "Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects." Advances in Therapy 37, no. 5 (2020): 2373-2390.
Cita MLA (9a ed.)
Kankam, Martin, et al. "Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects." Advances in Therapy, vol. 37, no. 5, 2020, pp. 2373-2390.
Precaución: Estas citas no son 100% exactas.